Founded in late 2018, KMPM is dedicated to the advancement of precision medicine that takes into account individual variability in genes, environment, and lifestyle to more accurately predict, detect, treat and ultimately defeat disease.
ALISO VIEJO, CALIF. - MARCH 19, 2019 - Konica Minolta Precision Medicine, Inc. (KMPM), a subsidiary of Konica Minolta, Inc. (Konica Minolta) today announced the formation of their inaugural Scientific Advisory Board.
Founded in late 2018, KMPM is dedicated to the advancement of precision medicine that takes into account individual variability in genes, environment, and lifestyle to more accurately predict, detect, treat and ultimately defeat disease.
”Our goal at KMPM is to uniquely unite genetics, imaging, pathology and artificial intelligence, uncovering the insights that enable pharmaceutical developers and clinicians to progress from sick care to healthcare—from reactive to preventive—and continuously improve quality of life,” stated Kiyotaka Fujii, Senior Managing Executive Director of Konica Minolta, Inc., Chairman and President of Konica Minolta Precision Medicine, Inc. “To achieve that goal, we must collaborate with the highest levels of expertise and we’ve certainly achieved that in our inaugural Scientific Advisory Board.”
John E. Niederhuber, MD, President and CEO of the Genomics and Bioinformatics Research Institute (GBRI), Fairfax, Virginia, a joint venture between Inova Health System and the University of Virginia, and former Director of both the National Cancer Institute and National Institutes of Health, has been named Chairman of KMPM’s Scientific Advisory Board.
Additional members are:
Judy Garber, MD, MPH, Susan F. Smith Chair and Chief of the Division of Cancer Genetics and Prevention at Dana-Farber Cancer Institute, and Professor of Medicine at Harvard Medical School. Dr. Garber has played a major role in the development of national guidelines in cancer genetics and is a leader in research into the characteristics and treatment of triple negative or basal-like breast cancer.
Geoffrey Ginsburg, MD, PhD, Founding Director, Center for Applied Genomics & Precision Medicine at the Duke University Medical Center. Dr. Ginsburg’s research addresses the challenges for translating genomic information into medical practice and integrating precision medicine into healthcare.
Giovanni Parmigiani, PhD, Associate Director for Population Sciences of the Multi-Institutional Dana-Farber/Harvard Cancer Center (DF/HCC), and Director of the Postdoctoral Training Grant in Quantitative Sciences for Cancer Research at the Harvard T.H. Chan School of Public Health, where he is a Professor. Dr. Parmigiani’s research focuses on finding innovative ways to use data science and data technologies to fuel cancer prevention.
David Rimm, MD, PhD, Professor, Departments of Pathology and Medicine (Oncology) at the Yale University School of Medicine, and Director of Yale Pathology Tissue Services. Dr. Rimm’s research lab group focuses on quantitative pathology to predict response to targeted and immune-therapy in cancer and standardization of those assays for CLIA labs.
Howard Scher, MD, Co-Chair, Center for Mechanism Based Therapy and Head of the Biomarker Development Initiative; Member and Attending Physician, Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center (MKSCC). Dr. Scher’s research focuses on the co-development of targeted therapies and biomarkers which can be used to guide treatment selection for individual patients, improve evaluation of drugs in the clinic, and accelerate regulatory approvals.
About Konica Minolta Precision Medicine
Konica Minolta Precision Medicine, Inc. (“KMPM”) based in Aliso Viejo, CA is a subsidiary of Konica Minolta, Inc. that includes Ambry Genetics Corporation and Invicro LLC. Founded in 2018 on the belief that groundbreaking medical breakthroughs are possible by concentrating efforts on the health expression map, the undiscovered territory between an individual’s genetics and biological impacts, and quantifiably measuring health over time. KMPM’s health intelligence and visualization platform brings together the most novel and diverse set of data from genes, proteins, cells and tissues with sophisticated analytics and world-leading scientific and medical expertise, enabling more prescriptive, proactive and preventive care. For further information, visit: http://www.KonicaMinoltaPrecisionMedicine.com
About Konica Minolta
Konica Minolta, Inc. (“Konica Minolta”) is a global digital technology company with core strengths in imaging and data analysis, optics, materials, and nano-fabrication. Through innovation, we create products and digital solutions for the betterment of business and society—today and for generations to come. Across our Business Technologies, Healthcare, and Industrial-facing businesses, we aspire to be an Integral Value Provider that applies the full range of our company’s expertise to offer comprehensive solutions to our customer’s most pressing problems, work with our partners to ensure our solutions are sustainable, anticipate and address tomorrow’s issues, and tailor each solution to meet the unique and specific needs of our valued customers. Leveraging these capabilities, Konica Minolta contributes to productivity improvement and workflow change for our customers and provides leading-edge service solutions in the IoT era. Headquartered in Tokyo and with operations in 50 countries, Konica Minolta has more than 43,000 employees serving approximately two million customers in over 150 countries. Konica Minolta is listed on the Tokyo Stock Exchange, (TSE4902). For further information, visit: http://www.KonicaMinolta.com
